TSRA-196
Gene therapy / editing
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
Other SERPINA1 drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Alpha-1 Antitrypsin Deficiency: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| TSRA-196: this drug | Phase 1/2 | Gene therapy / editing | SERPINA1 | not yet graded | No reviewed efficacy summary in this indication | |
| Fazirsiran | Phase 3 | RNA / oligonucleotide | SERPINA1 | not yet graded | No reviewed efficacy summary in this indication | |
| Alvelestat | Phase 2 | Small molecule | Neutrophil elastase | Partial signal | NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively). | |
| BEAM-302 | Phase 1/2 | Gene therapy / editing | SERPINA1 PiZ mutation (E342K) | not yet graded | No reviewed efficacy summary in this indication | |
| WVE-006 | Phase 1/2 | RNA / oligonucleotide | SERPINA1 Z-allele mRNA (ADAR-mediated editing) | not yet graded | No reviewed efficacy summary in this indication | |
| KB408 | Phase 1 | Gene therapy / editing | SERPINA1 (alpha-1 antitrypsin; gene replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| Efdoralprin Alfa | —(overall) | Protein / enzyme therapeutic | Alpha-1 antitrypsin (AAT) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow TSRA-196 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.